By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Lightlake Therapeutics Inc. 

445 Park Avenue, 9th Floor

New York  New York  10022  United Kingdom
Phone: 212-829-5546 Fax: 917-322-2105


SEARCH JOBS








Company News
Lightlake (LLTP) Announces Adapt Pharma To Offer All U.S. High Schools A Free Narcan (Naloxone Hydrochloride) Nasal Spray And Fund School-Based Opioid Overdose Education 1/27/2016 7:46:35 AM
Lightlake (LLTP) Announces Adapt Pharma Facilitates NARCAN (Naloxone Hydrochloride) Nasal Spray Access To 62,000 State And Local Public Entities 1/19/2016 7:42:04 AM
Lightlake (LLTP) Announces Collaboration With NIDA And The Perelman School Of Medicine At The University of Pennsylvania 12/23/2015 7:16:51 AM
Lightlake (LLTP) Receives Milestone Payment For U.S. FDA Approval Of NARCAN (Naloxone Hydrochloride) Nasal Spray 12/15/2015 7:36:53 AM
Lightlake (LLTP) Release: NARCAN (Naloxone Hydrochloride) Nasal Spray Approved By FDA 11/19/2015 7:34:17 AM
Lightlake Therapeutics Inc. (LLTP) Receives Second Funding Commitment From A Prominent International Research And Development Foundation 10/1/2015 7:30:57 AM
Lightlake Therapeutics Inc. (LLTP) Announces FDA Accepts For Review Adapt Pharma's NARCAN (Naloxone Hydrochloride) Nasal Spray NDA And Grants Priority Review Status 9/25/2015 7:20:27 AM
Lightlake Therapeutics Inc. (LLTP) Announces Adapt Pharma Limited Submits NDA To FDA For Narcan (naloxone) Nasal Spray 7/30/2015 10:38:04 AM
Lightlake Therapeutics Inc. (LLTP) Announces Adapt Pharma Limited Commences Rolling NDA Submission To The FDA For Intranasal Naloxone 6/3/2015 9:57:21 AM
Lightlake Therapeutics Inc. (LLTP) Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study 4/22/2015 11:31:18 AM
12345
//-->